| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urologic Neoplasms | 63 | 2024 | 319 | 16.900 |
Why?
|
| Carcinoma, Transitional Cell | 89 | 2024 | 798 | 15.620 |
Why?
|
| Urinary Bladder Neoplasms | 135 | 2024 | 2254 | 14.810 |
Why?
|
| Urothelium | 36 | 2021 | 275 | 7.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 123 | 2024 | 11844 | 6.120 |
Why?
|
| Kidney Neoplasms | 70 | 2018 | 4299 | 5.340 |
Why?
|
| Carcinoma, Renal Cell | 65 | 2018 | 3198 | 5.340 |
Why?
|
| Antineoplastic Agents | 99 | 2021 | 13709 | 4.320 |
Why?
|
| Cisplatin | 46 | 2021 | 1661 | 3.920 |
Why?
|
| Vinblastine | 25 | 2019 | 488 | 3.530 |
Why?
|
| Cystectomy | 32 | 2019 | 644 | 3.460 |
Why?
|
| Taxoids | 29 | 2019 | 669 | 3.370 |
Why?
|
| Salvage Therapy | 16 | 2018 | 1277 | 2.610 |
Why?
|
| Antibodies, Monoclonal | 30 | 2024 | 9261 | 2.370 |
Why?
|
| Molecular Targeted Therapy | 19 | 2019 | 2834 | 2.300 |
Why?
|
| Deoxycytidine | 25 | 2019 | 888 | 2.280 |
Why?
|
| Carcinoma | 20 | 2018 | 2341 | 2.250 |
Why?
|
| Benzenesulfonates | 12 | 2010 | 166 | 2.170 |
Why?
|
| Pyrroles | 17 | 2014 | 1127 | 2.140 |
Why?
|
| Paclitaxel | 16 | 2024 | 1737 | 1.990 |
Why?
|
| Neoplasm Metastasis | 48 | 2019 | 4931 | 1.970 |
Why?
|
| Disease-Free Survival | 59 | 2021 | 6856 | 1.900 |
Why?
|
| Indoles | 17 | 2014 | 1834 | 1.880 |
Why?
|
| Nomograms | 6 | 2018 | 236 | 1.830 |
Why?
|
| Prostatic Neoplasms | 44 | 2019 | 11206 | 1.820 |
Why?
|
| Immunotherapy | 20 | 2021 | 4728 | 1.810 |
Why?
|
| Angiogenesis Inhibitors | 17 | 2017 | 2062 | 1.580 |
Why?
|
| Survival Analysis | 55 | 2019 | 10127 | 1.530 |
Why?
|
| Ureteral Neoplasms | 5 | 2016 | 108 | 1.510 |
Why?
|
| Pyridines | 15 | 2019 | 2888 | 1.490 |
Why?
|
| Organoplatinum Compounds | 7 | 2017 | 408 | 1.440 |
Why?
|
| Chemotherapy, Adjuvant | 28 | 2018 | 3550 | 1.370 |
Why?
|
| Urogenital Neoplasms | 4 | 2015 | 133 | 1.300 |
Why?
|
| Protein Kinase Inhibitors | 18 | 2016 | 5709 | 1.250 |
Why?
|
| Endonucleases | 4 | 2017 | 371 | 1.150 |
Why?
|
| Humans | 399 | 2024 | 768369 | 1.130 |
Why?
|
| Neoadjuvant Therapy | 22 | 2019 | 2896 | 1.130 |
Why?
|
| Prognosis | 62 | 2019 | 30031 | 1.130 |
Why?
|
| Neoplasm Invasiveness | 27 | 2021 | 3637 | 1.120 |
Why?
|
| Carboplatin | 17 | 2019 | 798 | 1.110 |
Why?
|
| Niacinamide | 16 | 2014 | 419 | 1.060 |
Why?
|
| Treatment Outcome | 114 | 2024 | 65408 | 1.060 |
Why?
|
| Imidazoles | 7 | 2019 | 1174 | 1.050 |
Why?
|
| Platinum | 7 | 2018 | 222 | 1.050 |
Why?
|
| Phenylthiohydantoin | 6 | 2016 | 208 | 1.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 14 | 2018 | 637 | 1.010 |
Why?
|
| Phenylurea Compounds | 16 | 2014 | 532 | 0.990 |
Why?
|
| Neoplasm Staging | 40 | 2018 | 11249 | 0.980 |
Why?
|
| TOR Serine-Threonine Kinases | 10 | 2024 | 2067 | 0.970 |
Why?
|
| Bone Neoplasms | 13 | 2018 | 2562 | 0.940 |
Why?
|
| Male | 236 | 2024 | 364761 | 0.920 |
Why?
|
| Muscles | 5 | 2021 | 1582 | 0.910 |
Why?
|
| Antineoplastic Agents, Hormonal | 9 | 2016 | 1536 | 0.890 |
Why?
|
| Aged | 168 | 2024 | 171514 | 0.880 |
Why?
|
| Orchiectomy | 9 | 2015 | 466 | 0.880 |
Why?
|
| Drug Administration Schedule | 26 | 2024 | 4861 | 0.860 |
Why?
|
| Prostate-Specific Antigen | 18 | 2019 | 2483 | 0.850 |
Why?
|
| Benzoxazoles | 2 | 2024 | 92 | 0.830 |
Why?
|
| Androgen Receptor Antagonists | 5 | 2016 | 125 | 0.820 |
Why?
|
| Pyrimidines | 7 | 2024 | 3050 | 0.770 |
Why?
|
| Prostatectomy | 10 | 2017 | 1840 | 0.770 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2020 | 9425 | 0.770 |
Why?
|
| Vascular Endothelial Growth Factor A | 12 | 2018 | 3520 | 0.770 |
Why?
|
| Androgen Antagonists | 15 | 2018 | 1418 | 0.770 |
Why?
|
| Sirolimus | 9 | 2014 | 1542 | 0.770 |
Why?
|
| Survival Rate | 31 | 2019 | 12875 | 0.760 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2019 | 8636 | 0.750 |
Why?
|
| Adenocarcinoma | 15 | 2018 | 6400 | 0.750 |
Why?
|
| Middle Aged | 164 | 2024 | 223406 | 0.740 |
Why?
|
| Platinum Compounds | 6 | 2018 | 95 | 0.730 |
Why?
|
| Kaplan-Meier Estimate | 28 | 2018 | 6537 | 0.730 |
Why?
|
| Aged, 80 and over | 77 | 2024 | 59679 | 0.720 |
Why?
|
| Watchful Waiting | 5 | 2018 | 496 | 0.720 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2013 | 624 | 0.690 |
Why?
|
| Muscle Neoplasms | 4 | 2018 | 130 | 0.670 |
Why?
|
| Indazoles | 4 | 2018 | 306 | 0.660 |
Why?
|
| Clinical Trials, Phase III as Topic | 15 | 2015 | 876 | 0.630 |
Why?
|
| Female | 171 | 2024 | 396926 | 0.630 |
Why?
|
| Combined Modality Therapy | 22 | 2019 | 8559 | 0.620 |
Why?
|
| Urology | 4 | 2017 | 411 | 0.580 |
Why?
|
| Fluorouracil | 8 | 2014 | 1656 | 0.570 |
Why?
|
| Cancer Vaccines | 4 | 2014 | 1044 | 0.570 |
Why?
|
| Radium | 3 | 2018 | 72 | 0.570 |
Why?
|
| Radiotherapy | 7 | 2017 | 1510 | 0.550 |
Why?
|
| DNA Copy Number Variations | 6 | 2018 | 2046 | 0.550 |
Why?
|
| Morpholines | 2 | 2019 | 583 | 0.540 |
Why?
|
| Cytosine Deaminase | 1 | 2016 | 66 | 0.530 |
Why?
|
| Societies, Medical | 8 | 2019 | 3954 | 0.510 |
Why?
|
| Mutation | 21 | 2024 | 30235 | 0.510 |
Why?
|
| Gene Dosage | 3 | 2020 | 1221 | 0.510 |
Why?
|
| Health Planning Guidelines | 3 | 2014 | 151 | 0.500 |
Why?
|
| Radiopharmaceuticals | 4 | 2014 | 2731 | 0.500 |
Why?
|
| Methotrexate | 18 | 2015 | 1722 | 0.500 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 98 | 0.500 |
Why?
|
| Clinical Trials as Topic | 24 | 2018 | 8051 | 0.500 |
Why?
|
| Neovascularization, Pathologic | 7 | 2016 | 2643 | 0.500 |
Why?
|
| BCG Vaccine | 4 | 2018 | 383 | 0.490 |
Why?
|
| Prednisone | 7 | 2017 | 1568 | 0.490 |
Why?
|
| Perioperative Care | 4 | 2015 | 1046 | 0.490 |
Why?
|
| Follow-Up Studies | 32 | 2020 | 39429 | 0.480 |
Why?
|
| Infusions, Intravenous | 9 | 2017 | 2228 | 0.480 |
Why?
|
| DNA-Binding Proteins | 6 | 2019 | 9623 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2019 | 10358 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2017 | 5342 | 0.470 |
Why?
|
| Disease Progression | 25 | 2018 | 13643 | 0.460 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 3 | 2020 | 106 | 0.460 |
Why?
|
| Anilides | 3 | 2015 | 415 | 0.450 |
Why?
|
| Carcinoma in Situ | 3 | 2017 | 791 | 0.440 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 10784 | 0.430 |
Why?
|
| Kallikreins | 3 | 2016 | 221 | 0.430 |
Why?
|
| Adult | 95 | 2024 | 223528 | 0.420 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2016 | 1628 | 0.410 |
Why?
|
| Alpha Particles | 1 | 2012 | 29 | 0.410 |
Why?
|
| Spain | 9 | 2015 | 491 | 0.410 |
Why?
|
| Patient-Centered Care | 3 | 2012 | 1439 | 0.410 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 1104 | 0.410 |
Why?
|
| Lymph Node Excision | 8 | 2017 | 1276 | 0.410 |
Why?
|
| Gene Expression Profiling | 8 | 2018 | 9508 | 0.410 |
Why?
|
| Interferon-alpha | 9 | 2013 | 909 | 0.400 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2018 | 1149 | 0.400 |
Why?
|
| Serum Albumin | 1 | 2015 | 676 | 0.400 |
Why?
|
| Drugs, Investigational | 2 | 2011 | 213 | 0.390 |
Why?
|
| Sulfonamides | 3 | 2018 | 1988 | 0.390 |
Why?
|
| Fluorine Radioisotopes | 1 | 2014 | 425 | 0.380 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2018 | 3669 | 0.370 |
Why?
|
| Hyponatremia | 1 | 2013 | 281 | 0.370 |
Why?
|
| Designer Drugs | 1 | 2010 | 21 | 0.360 |
Why?
|
| Ifosfamide | 3 | 1998 | 234 | 0.360 |
Why?
|
| Receptor, erbB-2 | 4 | 2016 | 2586 | 0.360 |
Why?
|
| Muscle, Smooth | 5 | 2017 | 930 | 0.360 |
Why?
|
| Urinary Bladder | 6 | 2018 | 1160 | 0.350 |
Why?
|
| Proportional Hazards Models | 18 | 2017 | 12561 | 0.340 |
Why?
|
| Benzamides | 7 | 2018 | 1381 | 0.340 |
Why?
|
| Doxorubicin | 11 | 2015 | 2229 | 0.340 |
Why?
|
| Europe | 12 | 2017 | 3439 | 0.340 |
Why?
|
| Maximum Tolerated Dose | 5 | 2017 | 890 | 0.340 |
Why?
|
| Genomics | 6 | 2018 | 5912 | 0.340 |
Why?
|
| Quality of Life | 12 | 2018 | 13497 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 11 | 2018 | 7449 | 0.330 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2014 | 631 | 0.330 |
Why?
|
| Rectum | 1 | 2014 | 902 | 0.330 |
Why?
|
| Lymphatic Metastasis | 11 | 2017 | 2930 | 0.330 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 565 | 0.330 |
Why?
|
| Immunotherapy, Active | 1 | 2009 | 58 | 0.320 |
Why?
|
| Hemoglobins | 2 | 2017 | 1532 | 0.320 |
Why?
|
| Liver Neoplasms | 10 | 2017 | 4362 | 0.310 |
Why?
|
| Drug Carriers | 1 | 2013 | 712 | 0.310 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 2048 | 0.310 |
Why?
|
| Nitriles | 8 | 2016 | 984 | 0.310 |
Why?
|
| Sodium | 1 | 2013 | 1595 | 0.300 |
Why?
|
| Methionine | 1 | 2010 | 574 | 0.300 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2018 | 67 | 0.300 |
Why?
|
| Retrospective Studies | 38 | 2019 | 81835 | 0.290 |
Why?
|
| Interleukin-8 | 1 | 2011 | 705 | 0.290 |
Why?
|
| Neutropenia | 5 | 2017 | 892 | 0.290 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 107 | 0.290 |
Why?
|
| Sarcoma | 4 | 2011 | 1806 | 0.290 |
Why?
|
| Tetrahydroisoquinolines | 3 | 2014 | 81 | 0.290 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2010 | 1166 | 0.290 |
Why?
|
| Stomach Neoplasms | 4 | 2012 | 1484 | 0.290 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2013 | 665 | 0.280 |
Why?
|
| Thromboembolism | 2 | 2012 | 1005 | 0.280 |
Why?
|
| Predictive Value of Tests | 13 | 2018 | 15459 | 0.280 |
Why?
|
| Administration, Oral | 9 | 2019 | 4040 | 0.270 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 6657 | 0.270 |
Why?
|
| Palliative Care | 5 | 2012 | 3644 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2465 | 0.270 |
Why?
|
| Colon | 1 | 2014 | 1804 | 0.270 |
Why?
|
| Nephrectomy | 8 | 2017 | 949 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 711 | 0.260 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2018 | 109 | 0.260 |
Why?
|
| Drug Delivery Systems | 2 | 2016 | 2238 | 0.260 |
Why?
|
| MicroRNAs | 4 | 2017 | 3806 | 0.260 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2010 | 751 | 0.260 |
Why?
|
| Patient Selection | 9 | 2019 | 4266 | 0.260 |
Why?
|
| Prospective Studies | 21 | 2018 | 54913 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 2884 | 0.250 |
Why?
|
| Medical Oncology | 4 | 2018 | 2347 | 0.250 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2009 | 647 | 0.250 |
Why?
|
| Biological Products | 1 | 2014 | 937 | 0.240 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 3611 | 0.240 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2011 | 618 | 0.240 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2005 | 87 | 0.240 |
Why?
|
| Colorectal Neoplasms | 7 | 2016 | 6979 | 0.230 |
Why?
|
| Nails | 3 | 1991 | 298 | 0.230 |
Why?
|
| Time Factors | 27 | 2018 | 40271 | 0.230 |
Why?
|
| Lung Neoplasms | 14 | 2015 | 13589 | 0.220 |
Why?
|
| DNA Repair | 3 | 2018 | 2051 | 0.220 |
Why?
|
| Protective Agents | 2 | 2014 | 151 | 0.220 |
Why?
|
| Administration, Intravesical | 3 | 2018 | 92 | 0.210 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2018 | 1339 | 0.210 |
Why?
|
| Double-Blind Method | 11 | 2017 | 12450 | 0.210 |
Why?
|
| Treatment Failure | 5 | 2013 | 2655 | 0.210 |
Why?
|
| Molecular Chaperones | 3 | 2018 | 764 | 0.210 |
Why?
|
| Signal Transduction | 8 | 2016 | 23639 | 0.210 |
Why?
|
| Risk Assessment | 14 | 2018 | 24310 | 0.210 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 474 | 0.200 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 1170 | 0.200 |
Why?
|
| Thalidomide | 3 | 2017 | 885 | 0.200 |
Why?
|
| Bone Remodeling | 3 | 2018 | 583 | 0.190 |
Why?
|
| Tegafur | 3 | 1998 | 39 | 0.190 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 998 | 0.190 |
Why?
|
| Drug Synergism | 3 | 2019 | 1765 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 3619 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 4213 | 0.190 |
Why?
|
| Nanoparticles | 1 | 2013 | 1986 | 0.190 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 380 | 0.190 |
Why?
|
| Leucovorin | 4 | 1998 | 643 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 2964 | 0.190 |
Why?
|
| Italy | 2 | 2013 | 853 | 0.180 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 17149 | 0.180 |
Why?
|
| Risk Factors | 22 | 2018 | 74915 | 0.180 |
Why?
|
| RNA, Messenger | 7 | 2016 | 12813 | 0.180 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 2544 | 0.180 |
Why?
|
| Dioxoles | 2 | 2011 | 96 | 0.180 |
Why?
|
| Brachytherapy | 3 | 2017 | 1227 | 0.180 |
Why?
|
| Urinary Diversion | 2 | 2018 | 137 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2015 | 2525 | 0.180 |
Why?
|
| Bleomycin | 3 | 1991 | 495 | 0.180 |
Why?
|
| Alkaline Phosphatase | 2 | 2013 | 865 | 0.180 |
Why?
|
| Vinca Alkaloids | 2 | 2011 | 36 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2006 | 563 | 0.180 |
Why?
|
| Drug Therapy | 2 | 2014 | 504 | 0.170 |
Why?
|
| Breast Neoplasms | 16 | 2011 | 21157 | 0.170 |
Why?
|
| Cohort Studies | 16 | 2018 | 41782 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2014 | 4083 | 0.170 |
Why?
|
| Cyclin E | 1 | 2020 | 156 | 0.170 |
Why?
|
| Lymph Nodes | 5 | 2017 | 3472 | 0.170 |
Why?
|
| Patient Care Team | 2 | 2008 | 2526 | 0.170 |
Why?
|
| Animals | 19 | 2019 | 169424 | 0.160 |
Why?
|
| Hemangioendothelioma | 2 | 1990 | 112 | 0.160 |
Why?
|
| Genetic Variation | 1 | 2014 | 6607 | 0.160 |
Why?
|
| Breast Neoplasms, Male | 2 | 1998 | 212 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7895 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2019 | 165 | 0.160 |
Why?
|
| Benzodiazepines | 1 | 2005 | 1139 | 0.160 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 2 | 2016 | 43 | 0.160 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 147 | 0.150 |
Why?
|
| Bronchial Neoplasms | 2 | 1996 | 111 | 0.150 |
Why?
|
| Diphosphonates | 2 | 2013 | 635 | 0.150 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2018 | 125 | 0.150 |
Why?
|
| Adenine | 1 | 2024 | 993 | 0.150 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1781 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2012 | 1794 | 0.150 |
Why?
|
| Venous Thromboembolism | 3 | 2016 | 1881 | 0.150 |
Why?
|
| Androstenes | 3 | 2014 | 186 | 0.150 |
Why?
|
| Radioisotopes | 3 | 2018 | 516 | 0.150 |
Why?
|
| Asthenia | 1 | 2017 | 16 | 0.140 |
Why?
|
| Disease Management | 4 | 2017 | 2533 | 0.140 |
Why?
|
| Antidotes | 1 | 1998 | 138 | 0.140 |
Why?
|
| Gene Deletion | 2 | 2015 | 2674 | 0.140 |
Why?
|
| Heat-Shock Proteins | 2 | 2018 | 798 | 0.140 |
Why?
|
| Congresses as Topic | 2 | 2012 | 810 | 0.140 |
Why?
|
| Cyclin D1 | 1 | 1998 | 454 | 0.140 |
Why?
|
| Random Allocation | 2 | 2018 | 2399 | 0.130 |
Why?
|
| Cryosurgery | 3 | 2016 | 477 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 2 | 2011 | 5443 | 0.130 |
Why?
|
| Galectins | 1 | 2019 | 296 | 0.130 |
Why?
|
| Oncogene Proteins | 1 | 2020 | 718 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 330 | 0.130 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 784 | 0.130 |
Why?
|
| Neoplasms | 11 | 2018 | 22389 | 0.130 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 417 | 0.130 |
Why?
|
| Rosa | 1 | 2015 | 8 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 2 | 2013 | 119 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2018 | 590 | 0.130 |
Why?
|
| E2F3 Transcription Factor | 1 | 2015 | 36 | 0.130 |
Why?
|
| BRCA1 Protein | 2 | 2015 | 1158 | 0.120 |
Why?
|
| Androstenols | 2 | 2013 | 25 | 0.120 |
Why?
|
| Histone Code | 1 | 2016 | 160 | 0.120 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11139 | 0.120 |
Why?
|
| Oligonucleotides | 1 | 2018 | 564 | 0.120 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 191 | 0.120 |
Why?
|
| Internationality | 2 | 2017 | 1007 | 0.120 |
Why?
|
| Adenoma, Villous | 1 | 2014 | 14 | 0.120 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2017 | 462 | 0.120 |
Why?
|
| Kidney Pelvis | 1 | 2016 | 195 | 0.120 |
Why?
|
| Blood Cell Count | 1 | 2015 | 402 | 0.120 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 243 | 0.120 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1996 | 595 | 0.120 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 163 | 0.110 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 12096 | 0.110 |
Why?
|
| Cluster Analysis | 3 | 2017 | 2730 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 601 | 0.110 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1994 | 79 | 0.110 |
Why?
|
| Recombinant Proteins | 7 | 2014 | 6527 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1585 | 0.110 |
Why?
|
| Androstadienes | 2 | 2013 | 348 | 0.110 |
Why?
|
| Cystoscopy | 2 | 2012 | 132 | 0.110 |
Why?
|
| Geriatrics | 1 | 2018 | 390 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2017 | 550 | 0.110 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2014 | 88 | 0.110 |
Why?
|
| Remission Induction | 5 | 2010 | 2408 | 0.110 |
Why?
|
| Mutation, Missense | 3 | 2018 | 2590 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 1078 | 0.110 |
Why?
|
| Receptors, Androgen | 2 | 2018 | 1084 | 0.110 |
Why?
|
| Estrogen Antagonists | 2 | 2008 | 150 | 0.110 |
Why?
|
| Wilms Tumor | 2 | 1994 | 378 | 0.110 |
Why?
|
| Standard of Care | 1 | 2017 | 571 | 0.100 |
Why?
|
| Achievement | 1 | 2014 | 288 | 0.100 |
Why?
|
| Cyclophosphamide | 7 | 2000 | 2224 | 0.100 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 1992 | 171 | 0.100 |
Why?
|
| Biopsy | 6 | 2017 | 6816 | 0.100 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2014 | 161 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 3 | 2008 | 420 | 0.100 |
Why?
|
| Incidence | 6 | 2016 | 21552 | 0.100 |
Why?
|
| Leiomyoma | 1 | 1997 | 641 | 0.100 |
Why?
|
| Capillaries | 3 | 1991 | 756 | 0.100 |
Why?
|
| Constipation | 1 | 2017 | 570 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 3253 | 0.100 |
Why?
|
| HIV Seropositivity | 2 | 1995 | 963 | 0.100 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 1993 | 762 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 2819 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1706 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1062 | 0.100 |
Why?
|
| Seminoma | 1 | 2012 | 136 | 0.090 |
Why?
|
| Urinary Tract | 1 | 2014 | 305 | 0.090 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2011 | 99 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2016 | 727 | 0.090 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 802 | 0.090 |
Why?
|
| Microscopy | 3 | 1991 | 909 | 0.090 |
Why?
|
| Gene Frequency | 2 | 2015 | 3615 | 0.090 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2010 | 43 | 0.090 |
Why?
|
| Raynaud Disease | 1 | 1991 | 79 | 0.090 |
Why?
|
| Albumins | 1 | 2013 | 578 | 0.090 |
Why?
|
| DNA Damage | 2 | 2018 | 2461 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 2 | 2017 | 712 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2015 | 1091 | 0.090 |
Why?
|
| Geriatric Assessment | 3 | 2018 | 1422 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 2 | 2012 | 403 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 363 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 730 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 4774 | 0.090 |
Why?
|
| Drug Approval | 1 | 2017 | 817 | 0.090 |
Why?
|
| Cell Survival | 2 | 2019 | 5800 | 0.090 |
Why?
|
| Hemorrhage | 2 | 2012 | 3456 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2013 | 1909 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2018 | 2611 | 0.080 |
Why?
|
| Mitoxantrone | 1 | 1990 | 148 | 0.080 |
Why?
|
| Fatigue | 1 | 2017 | 1556 | 0.080 |
Why?
|
| Logistic Models | 6 | 2018 | 13323 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 9177 | 0.080 |
Why?
|
| Linear Models | 2 | 2010 | 5880 | 0.080 |
Why?
|
| Receptors, Growth Factor | 1 | 2010 | 326 | 0.080 |
Why?
|
| Half-Life | 1 | 2010 | 650 | 0.080 |
Why?
|
| Colonic Polyps | 1 | 2014 | 557 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 958 | 0.080 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 1368 | 0.080 |
Why?
|
| Consensus | 3 | 2019 | 3207 | 0.080 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2012 | 335 | 0.080 |
Why?
|
| Evidence-Based Medicine | 8 | 2014 | 3708 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 560 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 1669 | 0.080 |
Why?
|
| Observer Variation | 1 | 2015 | 2622 | 0.080 |
Why?
|
| Propensity Score | 4 | 2018 | 1970 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 1997 | 1423 | 0.080 |
Why?
|
| Thrombocytopenia | 2 | 2012 | 1183 | 0.080 |
Why?
|
| Codon | 1 | 2010 | 598 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2019 | 2987 | 0.080 |
Why?
|
| Recurrence | 2 | 2018 | 8510 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2010 | 2433 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2298 | 0.070 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 3734 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 988 | 0.070 |
Why?
|
| Progestins | 1 | 2009 | 302 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2017 | 9687 | 0.070 |
Why?
|
| Databases, Factual | 6 | 2018 | 8081 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2009 | 750 | 0.070 |
Why?
|
| Paresthesia | 1 | 1988 | 161 | 0.070 |
Why?
|
| Cell Line | 3 | 2018 | 15610 | 0.070 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2007 | 31 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 1998 | 3464 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 3832 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2008 | 171 | 0.070 |
Why?
|
| HEK293 Cells | 1 | 2016 | 4294 | 0.070 |
Why?
|
| Erythema | 1 | 1988 | 262 | 0.070 |
Why?
|
| S Phase | 1 | 2008 | 425 | 0.070 |
Why?
|
| G1 Phase | 1 | 2008 | 404 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2017 | 4425 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 614 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2014 | 1409 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2014 | 1412 | 0.070 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2008 | 305 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2009 | 1892 | 0.070 |
Why?
|
| Tamoxifen | 1 | 1991 | 968 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 6320 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2014 | 1062 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2014 | 1891 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1337 | 0.060 |
Why?
|
| Mice | 5 | 2019 | 82051 | 0.060 |
Why?
|
| Genetic Loci | 1 | 2015 | 2630 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2010 | 1496 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2017 | 15879 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2019 | 10490 | 0.060 |
Why?
|
| Heart Neoplasms | 1 | 1989 | 374 | 0.060 |
Why?
|
| Growth Substances | 2 | 1998 | 761 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2009 | 499 | 0.060 |
Why?
|
| Phenotype | 4 | 2016 | 16712 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2007 | 255 | 0.060 |
Why?
|
| Farnesyltranstransferase | 1 | 2005 | 71 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2823 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1364 | 0.060 |
Why?
|
| Health Status | 1 | 2018 | 4096 | 0.060 |
Why?
|
| Aging | 2 | 2018 | 8762 | 0.060 |
Why?
|
| Neutrophils | 1 | 2018 | 3790 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2007 | 475 | 0.060 |
Why?
|
| Tissue Extracts | 2 | 2016 | 139 | 0.060 |
Why?
|
| Risk | 3 | 2013 | 9642 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 4120 | 0.060 |
Why?
|
| United States | 6 | 2018 | 73120 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 5808 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 36840 | 0.060 |
Why?
|
| Comorbidity | 2 | 2011 | 10601 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 617 | 0.060 |
Why?
|
| Diarrhea | 2 | 2009 | 1320 | 0.060 |
Why?
|
| Esophageal Neoplasms | 2 | 2011 | 1676 | 0.060 |
Why?
|
| CpG Islands | 1 | 2008 | 1211 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2847 | 0.050 |
Why?
|
| Age Factors | 5 | 2018 | 18477 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2013 | 3442 | 0.050 |
Why?
|
| Naphthalenes | 2 | 2015 | 198 | 0.050 |
Why?
|
| Adolescent | 7 | 2021 | 89163 | 0.050 |
Why?
|
| Pleural Neoplasms | 1 | 2008 | 612 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 1136 | 0.050 |
Why?
|
| Young Adult | 8 | 2018 | 60038 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2008 | 774 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2010 | 1965 | 0.050 |
Why?
|
| Survival | 2 | 2013 | 161 | 0.050 |
Why?
|
| Pelvis | 2 | 2017 | 737 | 0.050 |
Why?
|
| Computational Biology | 1 | 2015 | 3549 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 3230 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 2910 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3412 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2016 | 1604 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2011 | 410 | 0.050 |
Why?
|
| Quinolones | 2 | 2017 | 382 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2014 | 2056 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 677 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 3 | 2014 | 797 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2009 | 1608 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2008 | 811 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2011 | 20763 | 0.050 |
Why?
|
| Tosyl Compounds | 1 | 2002 | 115 | 0.050 |
Why?
|
| Flutamide | 1 | 2002 | 95 | 0.050 |
Why?
|
| Safety | 2 | 2017 | 1159 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 1751 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 1990 | 1162 | 0.050 |
Why?
|
| Skin Diseases | 1 | 2010 | 1099 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2014 | 640 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2019 | 2942 | 0.050 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 3543 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2012 | 2102 | 0.050 |
Why?
|
| Kinetics | 1 | 2009 | 6347 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2016 | 3463 | 0.050 |
Why?
|
| North America | 2 | 2015 | 1292 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2018 | 2925 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2009 | 3164 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2004 | 648 | 0.040 |
Why?
|
| Algorithms | 3 | 2012 | 14157 | 0.040 |
Why?
|
| Drug Evaluation | 2 | 1992 | 642 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2006 | 809 | 0.040 |
Why?
|
| History, 21st Century | 2 | 2017 | 1575 | 0.040 |
Why?
|
| DNA | 1 | 2013 | 7213 | 0.040 |
Why?
|
| Actuarial Analysis | 2 | 1996 | 372 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2019 | 12176 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2017 | 1143 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 3710 | 0.040 |
Why?
|
| Registries | 1 | 2015 | 8372 | 0.040 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 15638 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 18047 | 0.040 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2018 | 29 | 0.040 |
Why?
|
| ras Proteins | 2 | 2016 | 1058 | 0.040 |
Why?
|
| Megestrol Acetate | 1 | 1998 | 18 | 0.040 |
Why?
|
| Smoking | 1 | 2015 | 9099 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6242 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2001 | 5308 | 0.040 |
Why?
|
| Models, Biological | 2 | 2014 | 9505 | 0.040 |
Why?
|
| Contrast Media | 1 | 2011 | 5337 | 0.040 |
Why?
|
| Orbital Neoplasms | 2 | 1991 | 223 | 0.040 |
Why?
|
| Forecasting | 1 | 2006 | 2950 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1990 | 2331 | 0.040 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2017 | 37 | 0.040 |
Why?
|
| International Agencies | 1 | 2017 | 245 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 20232 | 0.030 |
Why?
|
| Quinazolines | 2 | 2014 | 1376 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2017 | 173 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 1996 | 167 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 2 | 2011 | 1207 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1994 | 1376 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2002 | 716 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1749 | 0.030 |
Why?
|
| Kidney | 1 | 2011 | 7064 | 0.030 |
Why?
|
| Uracil | 1 | 1997 | 210 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2015 | 6353 | 0.030 |
Why?
|
| Radiography | 3 | 2015 | 6995 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2001 | 2079 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 306 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 245 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 895 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2019 | 714 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 5455 | 0.030 |
Why?
|
| Ureteroscopy | 1 | 2016 | 150 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 361 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2019 | 1503 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 132 | 0.030 |
Why?
|
| Gene Expression | 3 | 2014 | 7605 | 0.030 |
Why?
|
| Direct Service Costs | 1 | 2014 | 61 | 0.030 |
Why?
|
| Cell Movement | 2 | 2013 | 5223 | 0.030 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2014 | 55 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 1840 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 1998 | 518 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 2072 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 776 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 107 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 420 | 0.030 |
Why?
|
| Mitomycin | 2 | 1991 | 264 | 0.030 |
Why?
|
| Carcinoma, Large Cell | 1 | 1994 | 114 | 0.030 |
Why?
|
| Ureter | 1 | 2016 | 370 | 0.030 |
Why?
|
| Urologic Surgical Procedures | 1 | 2016 | 299 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 856 | 0.030 |
Why?
|
| Point Mutation | 1 | 1998 | 1596 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2016 | 592 | 0.030 |
Why?
|
| Child | 3 | 2017 | 80856 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2633 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2015 | 565 | 0.030 |
Why?
|
| Procollagen | 1 | 2013 | 189 | 0.030 |
Why?
|
| Choroid Neoplasms | 1 | 1994 | 177 | 0.030 |
Why?
|
| Immunity | 1 | 2018 | 1002 | 0.030 |
Why?
|
| Triazoles | 1 | 1998 | 905 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2014 | 278 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2016 | 578 | 0.020 |
Why?
|
| Publication Bias | 1 | 2013 | 160 | 0.020 |
Why?
|
| Expert Systems | 1 | 2012 | 79 | 0.020 |
Why?
|
| Anemia | 1 | 2002 | 1521 | 0.020 |
Why?
|
| Length of Stay | 2 | 2017 | 6521 | 0.020 |
Why?
|
| Asia | 1 | 2013 | 627 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 16023 | 0.020 |
Why?
|
| Polyarteritis Nodosa | 1 | 1992 | 70 | 0.020 |
Why?
|
| Papilloma | 1 | 1992 | 142 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2011 | 118 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 672 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2014 | 660 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1995 | 531 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 661 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2013 | 539 | 0.020 |
Why?
|
| Addison Disease | 1 | 1990 | 48 | 0.020 |
Why?
|
| Placebos | 1 | 2015 | 1668 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 635 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 1992 | 234 | 0.020 |
Why?
|
| Prostate | 1 | 2018 | 1781 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 1994 | 515 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2017 | 1249 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2012 | 962 | 0.020 |
Why?
|
| Hypertension | 1 | 2010 | 8610 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 1727 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2013 | 620 | 0.020 |
Why?
|
| Tonsillar Neoplasms | 1 | 1990 | 50 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 1996 | 1320 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1994 | 1232 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5426 | 0.020 |
Why?
|
| Mitomycins | 1 | 1989 | 46 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2011 | 321 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 1670 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 873 | 0.020 |
Why?
|
| Estrogens | 1 | 2015 | 1531 | 0.020 |
Why?
|
| Apoptosis | 1 | 2005 | 9526 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1997 | 1244 | 0.020 |
Why?
|
| Genetic Markers | 1 | 1994 | 2604 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1195 | 0.020 |
Why?
|
| Thrombophlebitis | 1 | 1989 | 289 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 2038 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2018 | 2696 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1997 | 1179 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2014 | 959 | 0.020 |
Why?
|
| Interferons | 1 | 1991 | 714 | 0.020 |
Why?
|
| Quinolines | 1 | 2013 | 769 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 1991 | 1503 | 0.020 |
Why?
|
| Salmonella Infections | 1 | 1989 | 172 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1997 | 2058 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2015 | 2772 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5042 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 6087 | 0.020 |
Why?
|
| Patient Preference | 1 | 2014 | 948 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 1502 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 551 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1779 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1997 | 2929 | 0.020 |
Why?
|
| Magnesium | 1 | 1990 | 816 | 0.020 |
Why?
|
| Heart Failure | 1 | 2011 | 11859 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 1386 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 1541 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1995 | 2170 | 0.020 |
Why?
|
| Acromegaly | 1 | 1989 | 316 | 0.020 |
Why?
|
| Piperidines | 1 | 2014 | 1664 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 1992 | 982 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2008 | 489 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1990 | 565 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1990 | 595 | 0.020 |
Why?
|
| Spinal Neoplasms | 1 | 1992 | 715 | 0.020 |
Why?
|
| Methylation | 1 | 2008 | 1077 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1994 | 928 | 0.020 |
Why?
|
| Epitopes | 1 | 2012 | 2523 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1990 | 736 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 681 | 0.020 |
Why?
|
| Lymphoma | 1 | 1994 | 1907 | 0.010 |
Why?
|
| Heterozygote | 1 | 2011 | 2792 | 0.010 |
Why?
|
| Cell Division | 2 | 2004 | 4479 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2009 | 633 | 0.010 |
Why?
|
| Hepatitis A virus | 1 | 2004 | 16 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 1688 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2015 | 3577 | 0.010 |
Why?
|
| Transgenes | 1 | 2008 | 1015 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2015 | 5893 | 0.010 |
Why?
|
| Foot | 1 | 1988 | 577 | 0.010 |
Why?
|
| Reoperation | 1 | 2014 | 4342 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 937 | 0.010 |
Why?
|
| Androgens | 1 | 2011 | 1285 | 0.010 |
Why?
|
| ROC Curve | 1 | 2011 | 3623 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2017 | 3308 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2015 | 2078 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 15965 | 0.010 |
Why?
|
| Hand | 1 | 1988 | 907 | 0.010 |
Why?
|
| Cerebellar Neoplasms | 1 | 1988 | 589 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2018 | 14483 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2004 | 387 | 0.010 |
Why?
|
| Menopause | 1 | 1991 | 1650 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2013 | 2589 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1990 | 1282 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 1766 | 0.010 |
Why?
|
| Syndrome | 1 | 1988 | 3278 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 751 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2013 | 5151 | 0.010 |
Why?
|
| Estradiol | 1 | 2008 | 1948 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1993 | 4948 | 0.010 |
Why?
|
| Vaccination | 1 | 2011 | 3433 | 0.010 |
Why?
|
| Binding Sites | 1 | 2008 | 6029 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2016 | 22286 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1992 | 2360 | 0.010 |
Why?
|
| Rats | 1 | 1994 | 23839 | 0.010 |
Why?
|
| Research Design | 1 | 2014 | 6217 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2006 | 2030 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 4534 | 0.010 |
Why?
|
| Vincristine | 2 | 1991 | 1039 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 4622 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 9376 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 9066 | 0.010 |
Why?
|
| Platelet Count | 1 | 1997 | 786 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 8730 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 12426 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 679 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 374 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 3922 | 0.010 |
Why?
|
| Stomatitis | 1 | 1995 | 271 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1995 | 437 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6135 | 0.010 |
Why?
|
| Procarbazine | 1 | 1991 | 172 | 0.010 |
Why?
|
| Lomustine | 1 | 1991 | 60 | 0.010 |
Why?
|
| Tuberculosis, Endocrine | 1 | 1990 | 1 | 0.010 |
Why?
|
| Fiber Optic Technology | 1 | 1993 | 291 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 1629 | 0.010 |
Why?
|
| Sputum | 1 | 1993 | 511 | 0.010 |
Why?
|
| Etoposide | 1 | 1991 | 640 | 0.010 |
Why?
|
| Adrenal Gland Diseases | 1 | 1990 | 141 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 26394 | 0.010 |
Why?
|
| Salmonella enteritidis | 1 | 1989 | 16 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1993 | 452 | 0.000 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1995 | 2589 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1990 | 1379 | 0.000 |
Why?
|
| Infant | 1 | 2010 | 36496 | 0.000 |
Why?
|
| Drug Resistance | 1 | 1993 | 1599 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1988 | 305 | 0.000 |
Why?
|
| Up-Regulation | 1 | 1996 | 4132 | 0.000 |
Why?
|
| Teratoma | 1 | 1990 | 405 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2010 | 42620 | 0.000 |
Why?
|
| Bronchoscopy | 1 | 1993 | 913 | 0.000 |
Why?
|
| Diagnosis, Differential | 2 | 1993 | 13025 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 3438 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 2004 | 11674 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 14725 | 0.000 |
Why?
|
| Lung | 1 | 1993 | 10090 | 0.000 |
Why?
|